Group 1 - The core viewpoint of the news is that Anjisi has shown a slight decline in stock price and trading volume, with specific details on financing and margin trading activities [1] - As of September 23, Anjisi's financing balance is 104 million yuan, accounting for 3.43% of its market capitalization, which is below the 20th percentile level over the past year, indicating a low financing level [1] - The company has not engaged in any short selling activities on September 23, with a margin balance of 0, which is at the 90th percentile level over the past year, indicating a high level of short selling potential [1] Group 2 - As of September 20, the number of shareholders in Anjisi decreased by 15.19% to 4,779, while the average circulating shares per person increased by 17.91% to 8,666 shares [2] - For the first half of 2025, Anjisi reported a revenue of 302 million yuan, representing a year-on-year growth of 14.56%, and a net profit attributable to shareholders of 126 million yuan, with a growth rate of 1.26% [2] - Since its A-share listing, Anjisi has distributed a total of 239 million yuan in dividends [2]

Core Viewpoint - The report outlines the ongoing supervision and assessment of Hangzhou Anjisi Medical Technology Co., Ltd. by CITIC Securities, focusing on the company's compliance, financial performance, and potential risks in the medical device industry [1][2]. Group 1: Continuous Supervision Overview - CITIC Securities conducted a site inspection on July 14, 2025, as part of its ongoing supervisory responsibilities [1]. - The supervision included reviewing corporate governance documents, financial management systems, and fundraising management practices [1]. Group 2: Identified Issues and Rectification - No major issues were found during the supervision period, indicating effective management practices [2]. - The company faces core competitiveness risks due to the lengthy and complex nature of developing minimally invasive endoscopic devices [2][3]. Group 3: Major Risk Factors - The company is exposed to operational risks from increasing competition in the domestic market and potential price reductions due to healthcare cost control measures [2][4]. - Quality control is critical, as any product defects could harm the company's reputation and financial performance [3][4]. Group 4: Financial Performance - For the first half of 2025, the company reported a revenue of 302.43 million yuan, a 14.56% increase from the previous year [11]. - The total profit for the same period was 149.13 million yuan, reflecting a 2.78% increase [11]. - The net profit attributable to shareholders was 111.51 million yuan, showing a decrease of 7.06% when excluding non-recurring gains [11]. Group 5: Research and Development - The company has increased its R&D investment, with total R&D expenses reaching 34.46 million yuan, a 33.29% increase compared to the previous period [18]. - R&D efforts focus on innovative diagnostic and therapeutic devices, with a strong emphasis on integrating AI technologies [12][18]. Group 6: Market Dynamics - The company is expanding its market presence, with significant sales growth in Europe (38.28%) and Asia (29.05%), while facing a decline in North America (9.89%) due to trade tensions [16]. - The company actively adapts to new procurement policies and payment regulations in the healthcare sector to maintain competitiveness [8][9]. Group 7: Compliance and Governance - The company adheres to various international and domestic quality management standards, ensuring compliance in its operations [13]. - There were no significant violations of fundraising regulations during the supervision period, indicating sound financial governance [21][24].

Company Overview - Anjess Medical Technology Co., Ltd. is located in Hangzhou, Zhejiang Province, and was established on December 6, 2010. The company went public on May 19, 2023. Its main business involves the research, development, production, and sales of endoscopic minimally invasive diagnostic and therapeutic devices [1][2]. Financial Performance - For the first half of 2025, Anjess achieved operating revenue of 302 million yuan, representing a year-on-year growth of 14.56%. The net profit attributable to the parent company was 126 million yuan, with a year-on-year increase of 1.26% [2]. - Since its A-share listing, Anjess has distributed a total of 239 million yuan in dividends [3]. Stock Performance - As of August 22, Anjess's stock price was 82.37 yuan per share, with a market capitalization of 6.67 billion yuan. The stock has increased by 41.25% year-to-date, but has seen a slight decline of 0.19% over the last five trading days and 0.16% over the last twenty days [1]. - The stock's trading volume on August 22 was 26.16 million yuan, with a turnover rate of 0.76%. The net outflow of main funds was 3.83 million yuan, with large orders accounting for 14.80% of purchases and 29.44% of sales [1]. Shareholder Information - As of August 20, the number of shareholders for Anjess was 5,293, a decrease of 1.34% from the previous period. The average number of circulating shares per person increased by 1.36% to 7,824 shares [2]. - As of June 30, 2025, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders [3]. Business Segmentation - Anjess's main business revenue composition is as follows: GI category 62.74%, EMR/ESD category 23.26%, ERCP category 11.04%, instruments category 2.21%, and others 0.74% [1].

Core Viewpoint - The A-share market experienced significant gains during the week of August 11 to 15, with the Shanghai Composite Index rising by 1.69%, the Shenzhen Component Index increasing by 4.55%, and the ChiNext Index surging by 8.58% [3]. Market Performance - The performance of the primary industries was mixed, with non-bank financials leading the gains at 7.07%, followed by electronics, power equipment, and non-ferrous metals [4]. - The week saw a notable rotation in themes, with stablecoins, PEEK materials, optical modules (CPO), and fintech showing prominent performance [4]. - Approximately 70% of the companies that were subject to institutional research achieved positive returns, with Hai Neng Technology rising over 42% and several others, including Feilong Co., Changcheng Securities, and Zhejiang Huaye, seeing increases of over 30% [4]. Institutional Research Highlights - Notable companies receiving extensive institutional research included Nanwei Medical and Anjisi, both in the medical device sector, with 183 and 180 institutions respectively participating in their research [5]. - Nanwei Medical reported a revenue of 1.565 billion yuan for the first half of the year, a 17.36% increase year-on-year, and a net profit of 363 million yuan, up 17.04% [5]. - The company has a strong international presence, with overseas revenue growing by 45%, accounting for 58% of total revenue [5][7]. Company Developments - Nanwei Medical is focusing on overseas expansion, with a local team of over 400 and plans for acquisitions to drive growth [7]. - Anjisi reported a revenue of 302 million yuan for the first half of the year, a 14.56% increase, and a net profit of 126 million yuan, up 1.26% [7]. - Anjisi's domestic sales gross margin was 67.58%, slightly down due to the impact of centralized procurement on high-margin products [9]. Mergers and Acquisitions - Jin Chengzi, a laser control system company, accepted research from 166 institutions and announced plans to acquire 55% of Samit, aiming for synergy in product categories and customer resources [11]. - New Qianglian, which specializes in large slewing bearings, received research from 162 institutions and reported a turnaround with a net profit of 400 million yuan in the first half of the year, compared to a loss of 101 million yuan in the same period last year [13]. - The company is focusing on enhancing its production efficiency and reducing costs through vertical integration and optimizing its product structure [13].

Market Overview - A-shares experienced a significant increase from August 11 to 15, with the Shanghai Composite Index rising by 1.69% to close at 3696.77 points, the Shenzhen Component Index increasing by 4.55%, and the ChiNext Index up by 8.58% [1] - The non-bank financial sector led the gains with a 7.07% increase, while industries such as banking, steel, and defense showed weaker performance [1] - The week saw a notable rotation in themes, with stablecoins, PEEK materials, optical modules (CPO), and fintech performing prominently [1] Institutional Research - The concentration of institutional research increased, with 67 listed companies disclosing research records by August 15 [1] - Approximately 70% of the companies that were researched reported positive returns, with HaiNeng Technology surging over 42% and several others, including Feilong Co., Changcheng Securities, and Zhejiang Huaye, seeing gains exceeding 30% [1] Company Highlights: Nanwei Medical - Nanwei Medical reported a revenue of 1.565 billion yuan for the first half of the year, a 17.36% increase year-on-year, and a net profit of 363 million yuan, up 17.04% [2] - The company's overseas revenue grew by 45%, accounting for 58% of total revenue, indicating strong international performance [2] - Nanwei Medical focuses on minimally invasive medical devices, with products covering over 90 countries [2] Company Highlights: Anjisi - Anjisi reported a revenue of 302 million yuan for the first half of the year, a 14.56% increase, and a net profit of 126 million yuan, showing a 1.26% growth [4] - The company faced challenges with a decrease in gross margin to 67.58% due to the impact of centralized procurement on high-margin products [5] - Anjisi is actively expanding its marketing network and adapting to ongoing healthcare policy reforms [5] Company Highlights: Jinchengzi - Jinchengzi announced plans to acquire a 55% stake in Samit, aiming to enhance product synergy and technical collaboration [7] - The acquisition is expected to strengthen Jinchengzi's competitive position in high-end precision optics and laser applications [7] Company Highlights: Xinqianglian - Xinqianglian reported a turnaround with a net profit of 400 million yuan in the first half of the year, compared to a loss of 101 million yuan in the same period last year [8] - The company improved its gross margin significantly and attributed its profitability to various cost-reduction strategies and enhanced production efficiency [9] - Xinqianglian is focusing on the wind power bearing business, with strong demand and a full order book for the second half of the year [9]

Core Viewpoint - Anjess Medical Technology Co., Ltd. reported a revenue of 302 million yuan for the first half of 2025, marking a year-on-year growth of 14.56%, with a net profit of 126 million yuan, reflecting a growth of 1.26% [1] Group 1: Financial Performance - The company achieved a revenue of 302 million yuan, representing a 14.56% increase year-on-year [1] - The net profit attributable to shareholders was 126 million yuan, showing a growth of 1.26% [1] Group 2: R&D Investment - Anjess emphasizes innovation as a key driver for growth, with R&D investment reaching 34.46 million yuan, up 33.29% year-on-year [1] - The company is actively working on 19 design improvement projects for existing products, 40 new product development projects, and 5 preliminary research projects [1] - The subsidiary Hang An Medical Technology (Hangzhou) Co., Ltd. is also advancing R&D with 12 new product development projects and 9 preliminary research projects [1] Group 3: Market Expansion - The domestic market sales revenue was 137 million yuan, an increase of 10.07% year-on-year, while overseas market sales reached 163 million yuan, up 18.29% [2] - Anjess has successfully sold products to over 60 countries across six continents, adding 14 new overseas clients during the reporting period, bringing the total to 130 [2] Group 4: Global Strategy - The company is enhancing its global competitiveness through a globalization strategy, focusing on local operational capabilities [3] - The Dutch subsidiary is operational, improving service capabilities and brand influence in Europe, while the U.S. subsidiary is in preparation to expand into North America [3] - A digital factory is being established in Thailand to integrate automation, smart manufacturing, and green management, aimed at increasing overall capacity and optimizing production layout [3] Group 5: Market Challenges and Opportunities - The company faces challenges in entering the European and American markets due to rising compliance costs and increased concentration of overseas channels, which compresses bargaining power [3] - The micro-invasive technology market in China is expected to grow, providing opportunities for Anjess to focus on smaller endoscope platforms and accelerate product registration [3]

本次发行股票拟在科创板上市，科创板公司具有研发投入大、经营风险 高、业绩不稳定、退市风险高等特点，投资者面临较大的市场风险。投资者应 充分了解科创板的投资风险及本公司所披露的风险因素，审慎作出投资决定。 杭州安杰思医学科技股份有限公司 （浙江省杭州市余杭区康信路 597 号 5 幢、6 幢（除 103 室、202 室）） 首次公开发行股票并在科创板上市 招股说明书 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 杭州安杰思医学科技股份有限公司 招股说明书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发行 人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担 股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 杭州安杰思医学科技股份有限公司 招股说明书 本次发 ...

本次发行股票拟在科创板上市，科创板公司具有研发投入大、经营风险 高、业绩不稳定、退市风险高等特点，投资者面临较大的市场风险。投资者应 充分了解科创板的投资风险及本公司所披露的风险因素，审慎作出投资决定。 杭州安杰思医学科技股份有限公司 （浙江省杭州市余杭区康信路 597 号 5 幢、6 幢（除 103 室、202 室）） 首次公开发行股票并在科创板上市 招股意向书 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 保荐人（主承销商） 杭州安杰思医学科技股份有限公司 招股意向书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发行 人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担 股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 杭州安杰思医学科技股份有限公司 招股意向书 本次发 ...

本次发行股票拟在科创板上市，科创板公司具有研发投入大、经营风险 高、业绩不稳定、退市风险高等特点，投资者面临较大的市场风险。投资者 应充分了解科创板的投资风险及本公司所披露的风险因素，审慎作出投资决 定。 杭州安杰思医学科技股份有限公司 （浙江省杭州市余杭区康信路 597 号 5 幢、6 幢（除 103 室、202 室）） 首次公开发行股票并在科创板上市 招股说明书 （注册稿） 本公司的发行申请尚需经上海证券交易所和中国证监会履行相应程序。 本招股说明书（注册稿）不具有据以发行股票的法律效力，仅供预先披露之 用。投资者应当以正式公告的招股说明书全文作为作出投资决定的依据。 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 杭州安杰思医学科技股份有限公司 招股说明书（注册稿） 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收 ...